معرفی
Rickard Ljung is an Adjunct Professor of Pharmacoepidemiology at Karolinska Institutet's Institute of Environmental Medicine and a Professor & Head of Pharmacoepidemiology at the Swedish Medical Products Agency. He specializes in drug safety surveillance, focusing on adverse reactions and vaccine efficacy. His research combines national health registries to assess risks like myocarditis post-vaccination and thyroid cancer from GLP-1 agonists. Key roles include advising regulatory policies during the pandemic and managing drug shortages.
Education: Medical degree (1994), PhD in Global Public Health (2006), Docent (2012), all from Karolinska Institutet.
Research spans epidemiology, oncology, and psychiatry, with emphasis on vaccine safety, drug prescribing patterns, and mental health outcomes. Notable grants include studies on bereavement cardiovascular risks and social determinants of brain tumors.
Recent articles analyze XBB.1.5 vaccine efficacy, opioid prescribing trends, and pulmonary embolism risks. He collaborates across Nordic countries and leads the Cancer Epidemiology and Causal Inference group under Maria Feychting.
